Vancomycin
Based on 100 publication(s) in Google Scholar
Vancomycin is an antibiotic for the treatment of bacterial infections.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.39%
- CAS. Nr.: 1404-90-6
- Formel: C66H75Cl2N9O24
- Molecular Weight:1449.25
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Vancomycin
More- Cancer Cell. 2025 Sep 25:S1535-6108(25)00394-0. [Abstract]
- Science. 2026 Mar 19;391(6791):eadu7686. [Abstract]
- Cell Metab. 2025 Jan 7;37(1):87-103.e10. [Abstract]
- Cell Metab. 2023 Nov 7;35(11):1961-1975.e6. [Abstract]
- Immunity. 2026 Mar 10;59(3):598-617.e11. [Abstract]
- Immunity. 2026 Mar 27:S1074-7613(26)00086-5. [Abstract]
- Cell Host Microbe. 2026 Jul 8;34(7):1350-1366.e8. [Abstract]
- Cancer Res. 2026 May 15. [Abstract]
- Adv Funct Mater. 2024 Jun 19.
- Redox Biol. 2023 Nov:67:102929. [Abstract]
- Gut Microbes. 2026 Dec 31;18(1):2620125. [Abstract]
- Gut Microbes. 2023 Dec;15(2):2249143. [Abstract]
- Adv Sci (Weinh). 2025 Oct 13:e09383. [Abstract]
- Adv Sci (Weinh). 2025 May;12(20):e2409837. [Abstract]
- Cell Rep Med. 2025 Oct 21;6(10):102410. [Abstract]
- Chem Eng J. 2024 Apr 15, 486 150125.
- Pharmacol Res. 2024 Jul:205:107229. [Abstract]
- Cell Death Dis. 2021 Jun 7;12(6):582. [Abstract]
- Small. 2022 Mar;18(10):e2107137. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- J Neuroinflammation. 2025 Nov 4;22(1):259. [Abstract]
- NPJ Biofilms Microbiomes. 2024 Oct 28;10(1):111. [Abstract]
- Phytomedicine. 2025 Jan:136:156297. [Abstract]
- J Pharm Anal. 2023 Oct;13(10):1153-1167. [Abstract]
- Environ Health Perspect. 2022 Jun;130(6):67009. [Abstract]
- Sci China Life Sci. 2026 Apr;69(4):1271-1283. [Abstract]
- Genome Biol. 2023 Apr 30;24(1):98. [Abstract]
- Food Res Int. 2026 Jul 31:236:119200. [Abstract]
- Int J Biol Macromol. 2025 May;307(Pt 4):142276. [Abstract]
- Int J Biol Macromol. 2024 Nov;281(Pt 4):135835. [Abstract]
- Neural Regen Res. 2024 Sep 1;19(9):2081-2088. [Abstract]
- Cancer Immunol Res. 2022 Dec 2;10(12):1542-1558. [Abstract]
- Am J Chin Med. 2024;52(5):1527-1554. [Abstract]
- Curr Res Food Sci. 2025 May 16:10:101084. [Abstract]
- Cell Rep. 2025 Feb 28;44(3):115356. [Abstract]
- Emerg Microbes Infect. 2024 Dec;13(1):2321981. [Abstract]
- Emerg Microbes Infect. 2022 Dec;11(1):815-828. [Abstract]
- Virulence. 2024 Dec;15(1):2415952. [Abstract]
- Virulence. 2024 Dec;15(1):2367659. [Abstract]
- J Agric Food Chem. 2024 Apr 10. [Abstract]
- Microb Biotechnol. 2021 Nov;14(6):2538-2551. [Abstract]
- Biochem Pharmacol. 2024 Dec;230(Pt 2):116593. [Abstract]
- Life Sci. 2026 Jul 15:397:124438. [Abstract]
- Life Sci. 2020 Nov 15:261:118473. [Abstract]
- Food Funct. 2026 Apr 14;17(7):3324-3335. [Abstract]
- Life Metab. 2025 Oct 8.
- Food Funct. 2025 Jul 14;16(14):5885-5899. [Abstract]
- Transl Res. 2023 Mar:253:16-30. [Abstract]
- Biomacromolecules. 2025 Jun 9;26(6):3852-3867. [Abstract]
- Front Microbiol. 2020 Jul 31:11:1720. [Abstract]
- Int Immunopharmacol. 2025 Jun 26:159:114888. [Abstract]
- BMC Microbiol. 2026 Apr 29. [Abstract]
- Front Pharmacol. 2025 Dec 1:16:1657343. [Abstract]
- ACS Omega. 2023 Mar 6;8(10):9652-9661. [Abstract]
- ACS Omega. 2023 Feb 3;8(6):5415-5425. [Abstract]
- Front Aging Neurosci. 2022 Jul 28;14:858130. [Abstract]
- ACS Omega. 2022 Mar 3;7(10):9004-9014. [Abstract]
- PLoS Pathog. 2025 Jun 9;21(6):e1013179. [Abstract]
- Mol Pharm. 2022 Nov 7;19(11):4320-4332. [Abstract]
- Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702. [Abstract]
- ACS Infect Dis. 2026 Feb 13;12(2):623-636. [Abstract]
- ACS Infect Dis. 2025 Jun 13;11(6):1473-1485. [Abstract]
- iScience. 2025 May 13;28(7):112658. [Abstract]
- iScience. 2025 May 27;28(6):112763. [Abstract]
- ACS Infect Dis. 2024 Aug 9;10(8):2961-2977. [Abstract]
- ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]
- ACS Infect Dis. 2023 Dec 8;9(12):2523-2537. [Abstract]
- iScience. 2023 Oct 7;26(11):108158. [Abstract]
- iScience. 2023 Mar 11;26(4):106378. [Abstract]
- iScience. 2022 Jan 5;25(2):103731. [Abstract]
- ACS Infect Dis. 2021 Aug 13;7(8):2565-2582. [Abstract]
- Aquaculture. 2021, 736248.
- Microbiol Spectr. 2025 Oct 23:e0157625. [Abstract]
- Microbiol Spectr. 2025 Oct 15:e0122125. [Abstract]
- Microbiol Spectr. 2022 Apr 27;10(2):e0054121. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):3681-3695. [Abstract]
- J Cell Physiol. 2022 Mar;237(3):1845-1856. [Abstract]
- AMB Express. 2026 May 20. [Abstract]
- Pathology. 2026 Feb 6:S0031-3025(26)00393-4. [Abstract]
- AMB Express. 2024 Dec 24;14(1):141. [Abstract]
- Mol Immunol. 2022 Sep:149:94-106. [Abstract]
- Int J Med Sci. 2022 Apr 11;19(4):740-752. [Abstract]
- Microbiologyopen. 2025 Oct;14(5):e70062. [Abstract]
- Infect Drug Resist. 2021 Dec 16;14:5449-5456. [Abstract]
- PLoS One. 2025 Jul 10;20(7):e0328167. [Abstract]
- J Appl Microbiol. 2024 Jan 2;135(1):lxae001. [Abstract]
- Curr Microbiol. 2023 May 31;80(7):230. [Abstract]
- J Med Microbiol. 2020 Jan;69(1):120-131. [Abstract]
- Future Microbiol. 2025 Oct 13:1-10. [Abstract]
- Biochem Biophys Res Commun. 2025 Aug 30:776:152161. [Abstract]
- Basic Clin Androl. 2025 Mar 7;35(1):9. [Abstract]
- Pol J Microbiol. 2023 Jun 14;72(2):199-208. [Abstract]
- ArXiv. 2025 Nov 7.
- bioRxiv. 2025 February 13.
- Research Square Preprint. 2024 Nov 13.
- Res Sq. 2024 Oct 02.
- bioRxiv. 2024 May 10.
- Heliyon. 2024 Jan 6;10(1):e24239. [Abstract]
- Research Square Preprint. 2020 Jun.
- Chemosphere. 2019 Jun:225:378-387. [Abstract]
Customer Validation & Images
-
WB
-
RT-PCR
-
IHC
-
WB
-
IHC
Alle Antibiotic Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Glycopeptide |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 3LL cell line | IC50 |
>1 mM
Compound: Vancomycin
|
Cytotoxicity against mouse LLC cells assessed as reduction in cell viability
Cytotoxicity against mouse LLC cells assessed as reduction in cell viability
|
[PMID: 36331380] |
| CCRF-CEM | IC50 |
>500 μM
Compound: 1
|
Inhibitory concentration against proliferation of human T-lymphocytic (CEM) cells
Inhibitory concentration against proliferation of human T-lymphocytic (CEM) cells
|
[PMID: 12801238] |
| HEK293 | CC50 |
>1000 μg/mL
Compound: Vancomycin
|
Cytotoxicity against HEK293 cells after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells after 72 hrs by MTT assay
|
[PMID: 24139168] |
| HEK293 | CC50 |
>100 μM
Compound: Vancomycin
|
Cytotoxicity against HEK293 cells after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells after 72 hrs by MTT assay
|
[PMID: 24751446] |
| HEK293 | CC50 |
>100 μM
Compound: Vancomycin
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay
|
[PMID: 30392371] |
| HEK-293T | IC50 |
>320 μM
Compound: Vancomycin
|
Antiproliferative activity against HEK293T cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
Antiproliferative activity against HEK293T cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
|
[PMID: 38173250] |
| L02 | IC50 |
>20 μM
Compound: Vancomycin
|
Cytotoxicity against human LO2 cells
Cytotoxicity against human LO2 cells
|
[PMID: 33811991] |
| L02 | IC50 |
>30 μM
Compound: Vancomycin
|
Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay
Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay
|
[PMID: 35398730] |
| L02 | IC50 |
>43 μg/mL
Compound: Vancomycin
|
Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay
Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay
|
[PMID: 35398730] |
| L02 | IC50 |
>64 μg/mL
Compound: Van
|
Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 38096652] |
| L1210 | IC50 |
>500 μM
Compound: 1
|
Inhibitory concentration of compound against proliferation of murine lukemia cells L1210 was determined
Inhibitory concentration of compound against proliferation of murine lukemia cells L1210 was determined
|
[PMID: 12801238] |
| L1210 | IC50 |
>1000 μg/mL
Compound: vancomycin
|
Cytotoxicity against mouse L1210 cells assessed as cell viability by trypan blue assay
Cytotoxicity against mouse L1210 cells assessed as cell viability by trypan blue assay
|
[PMID: 9051915] |
| L1210 | IC50 |
>1000 μg/mL
Compound: vancomycin
|
Cytotoxicity against mouse L1210 cells by MTT assay
Cytotoxicity against mouse L1210 cells by MTT assay
|
[PMID: 9051915] |
| MOLT-4 | IC50 |
>500 μM
Compound: 1
|
Inhibitory concentration of compound against proliferation of human T-lymphocytic cells MOLT-4/C8 was determined
Inhibitory concentration of compound against proliferation of human T-lymphocytic cells MOLT-4/C8 was determined
|
[PMID: 12801238] |
Vancomycin is a large glycopeptide compound with a molecular weight of 1450 Da[1]. Vancomycin is a unique glycopeptide structurally unrelated to any currently available antibiotic. It also has a unique mode of action inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin is active against a large number of species of Gram-positive bacteria, such as Staphylococcus aureus, Staph. epidermidis, Str. agalactiae, Str. bovis, Str. mutans, viridans streptococci, enterococci[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J male mice[4]
-
Dosage:400 mg/kg/day, 7 day
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Caused renal injury with a higher renal injury score and kidney index.
Induced cell apoptosis and increase in kidney Cr, BUN, MDA, IL-1β, IL-6, TNF-α, and NF-κB.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Vancomycin can be used to induce renal injury models[4].
Administration: 400 mg/kg • ip • once daily for 7 weeks
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 1404-90-6
-
Appearance Solid
-
Molecular Weight 1449.25
-
Formel C66H75Cl2N9O24
-
Color White to light yellow
-
SMILES
O[C@@H]1[C@@H](O[C@@](O[C@@H](C)[C@H]2O)([H])C[C@@]2(N)C)[C@@H](O[C@H](CO)[C@H]1O)OC3=C(OC4=CC=C([C@H]([C@H]5NC([C@H](NC)CC(C)C)=O)O)C=C4Cl)C=C([C@](NC([C@@H](NC5=O)CC(N)=O)=O)([H])C(N[C@](C6=O)([H])C7=CC8=C(O)C=C7)=O)C=C3OC9=CC=C([C@H]([C@](C(N[C@@](C(O)=O)([H])C%10=C8C(O)=CC(O)=C%10)=O)([H])N6)O)C=C9Cl
-
Sequence
{d-Leu}-{d-Tyr}-Asn-{d-Nty}-{d-Nty}-Tyr-{Nty} (Covalent bridge:Tyr2-Nty4, Nty4-Tyr6, Nty5-Nty7)
-
Sequence Shortening
{d-Leu}-{d-Tyr}-N-{d-Nty}-{d-Nty}-Y-{Nty} (Covalent bridge:Tyr2-Nty4, Nty4-Tyr6, Nty5-Nty7)
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (100)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Ketogenic diet inhibits glioma progression by promoting gut microbiota-derived butyrate production. [Abstract]2025 Sep 25:S1535-6108(25)00394-0. PMID: 41005305 -
Science
Commensal-driven serotonin production modulates in vivo delivery of synthetic and viral vectors. [Abstract]2026 Mar 19;391(6791):eadu7686. PMID: 41855345 -
Cell Metab
Stress triggers irritable bowel syndrome with diarrhea through a spermidine-mediated decline in type I interferon. [Abstract]2025 Jan 7;37(1):87-103.e10. PMID: 39366386 -
Cell Metab
High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate. [Abstract]2023 Nov 7;35(11):1961-1975.e6. PMID: 37797623 -
Immunity
2026 Mar 10;59(3):598-617.e11. PMID: 41722568 -
Immunity
NF-κB-activated fibroblasts orchestrate inflammaging and emergence of pro-inflammatory granzyme K+ T cells. [Abstract]2026 Mar 27:S1074-7613(26)00086-5. PMID: 41903549 -
Cell Host Microbe
Gut bacteria that produce fatty acid ethanolamides alleviate diarrhea-predominant IBS with insulin resistance. [Abstract]2026 Jul 8;34(7):1350-1366.e8. PMID: 42320473 -
Cancer Res
Distinct Inflammatory Cytotoxic T Lymphocyte Populations Mediate PD-1 Blockade Induced Immune-Related Adverse Events in Multiple Organs. [Abstract]2026 May 15. PMID: 42139517 -
-
Redox Biol
Arginase2 mediates contrast-induced acute kidney injury via facilitating nitrosative stress in tubular cells. [Abstract]2023 Nov:67:102929. PMID: 37856999
Vancomycin purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Nov:67:102929. [Abstract]
ARG2 protein expressions in the kidneys of Vancomycin (500 mg/kg, daily, 7 days, ip)-induced AKI mice.
Vancomycin purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Nov:67:102929. [Abstract]
ARG2 mRNA expressions in the kidneys of Vancomycin (500 mg/kg, daily, 7 days, ip)-induced AKI mice.
Vancomycin purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Nov:67:102929. [Abstract]
Representative images of immunohistochemistry staining of ARG2 in Vancomycin (500 mg/kg, daily, 7 days, ip)-induced AKI mice kidneys. The red arrows indicate deeper ARG2-positive staining of renal tubules. Scale, 20×, 100 μm, 40×, 50 μm.
Vancomycin purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Nov:67:102929. [Abstract]
ARG2 protein expression in primary tubular epithelial cells treated by Vancomycin (4mM, 48 h).
Vancomycin purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Nov:67:102929. [Abstract]
Renal function and renal tissue injury of ARG2 KO and WT mice administrated with Vancomycin were assessed by SCr, BUN, and tubular injury score. The red arrows showed the vacuolar degeneration, tubular necrosis, cast formation, and tubular dilation of renal tubules.
-
Gut Microbes
Gut microbial ammonia as a mediator of PFOS neurotoxicity and its remediation by the flavonoid Icaritin. [Abstract]2026 Dec 31;18(1):2620125. PMID: 41629743 -
Gut Microbes
Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. [Abstract]2023 Dec;15(2):2249143. PMID: 37635362 -
Adv Sci (Weinh)
Faecalibaculum rodentium Alleviates Ionizing Radiation-Induced Damage in Mice by Improving Intestinal Integrity and Hematopoiesis via Its Metabolite Butyrate. [Abstract]2025 Oct 13:e09383. PMID: 41082369 -
Adv Sci (Weinh)
Microbiota-Derived Inosine Suppresses Systemic Autoimmunity via Restriction of B Cell Differentiation and Migration. [Abstract]2025 May;12(20):e2409837. PMID: 40289872 -
Cell Rep Med
Intestinal Lachnospiraceae bacterium-derived propionate inhibits the progression of clear cell renal cell carcinoma. [Abstract]2025 Oct 21;6(10):102410. PMID: 41067230 -
-
Pharmacol Res
Multi-omics approaches for the understanding of therapeutic mechanism for Huang-Qi-Long-Dan Granule against ischemic stroke. [Abstract]2024 Jul:205:107229. PMID: 38782148 -
Cell Death Dis
Effects of short-chain fatty acids in inhibiting HDAC and activating p38 MAPK are critical for promoting B10 cell generation and function. [Abstract]2021 Jun 7;12(6):582. PMID: 34099635 -
Small
Healing Diabetic Ulcers with MoO3-X Nanodots Possessing Intrinsic ROS-Scavenging and Bacteria-Killing Capacities. [Abstract]2022 Mar;18(10):e2107137. PMID: 34927361 -
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
J Neuroinflammation
The gut microbiota limits systemic inflammation during neurotrophic viral CNS infection by priming tonic type I interferon signaling. [Abstract]2025 Nov 4;22(1):259. PMID: 41189008 -
NPJ Biofilms Microbiomes
Gut microbiota dysbiosis-mediated ceramides elevation contributes to corticosterone-induced depression by impairing mitochondrial function. [Abstract]2024 Oct 28;10(1):111. PMID: 39468065 -
Phytomedicine
Sarsasapogenin stimulates angiogenesis and osteogenesis coupling to treat estrogen deficiency-induced osteoporosis by activating the GPX4/SLIT3/ROBO1 axis. [Abstract]2025 Jan:136:156297. PMID: 39637471 -
J Pharm Anal
Protective effects of dioscin against Parkinson's disease via regulating bile acid metabolism through remodeling gut microbiome/GLP-1 signaling. [Abstract]2023 Oct;13(10):1153-1167. PMID: 38024855 -
Environ Health Perspect
The Role of Fecal Microbiota in Liver Toxicity Induced by Perfluorooctane Sulfonate in Male and Female Mice. [Abstract]2022 Jun;130(6):67009. PMID: 35759388 -
Sci China Life Sci
Endometrial microbiota-dimethylglycine-Treg cell axis affects endometrial receptivity in recurrent implantation failure. [Abstract]2026 Apr;69(4):1271-1283. PMID: 41627665 -
Genome Biol
Caloric restriction remodels the hepatic chromatin landscape and bile acid metabolism by modulating the gut microbiota. [Abstract]2023 Apr 30;24(1):98. PMID: 37122023 -
Food Res Int
Fructooligosaccharides alleviate early-life antibiotic-exposed food allergy via the Indole-3-propionic acid-AhR-Nrf2 Axis: A multi-omics prospective cohort study. [Abstract]2026 Jul 31:236:119200. PMID: 42116470 -
Int J Biol Macromol
Salidroside attenuates NASH through regulating bile acid-FXR/TGR5 signaling pathway via targeting gut microbiota. [Abstract]2025 May;307(Pt 4):142276. PMID: 40118401 -
Int J Biol Macromol
Tremella aurantialba polysaccharides alleviate ulcerative colitis in mice by improving intestinal barrier via modulating gut microbiota and inhibiting ferroptosis. [Abstract]2024 Nov;281(Pt 4):135835. PMID: 39306158 -
Neural Regen Res
Gut microbiota dysbiosis contributes to α-synuclein-related pathology associated with C/EBPβ/AEP signaling activation in a mouse model of Parkinson's disease. [Abstract]2024 Sep 1;19(9):2081-2088. PMID: 38227539 -
Cancer Immunol Res
NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy. [Abstract]2022 Dec 2;10(12):1542-1558. PMID: 36255412 -
Am J Chin Med
Astragaloside IV Ameliorates Colonic Adenomatous Polyps Development by Orchestrating Gut Bifidobacterium and Serum Metabolome. [Abstract]2024;52(5):1527-1554. PMID: 39164214 -
Curr Res Food Sci
Gallic acid prevents obesity in mice on a high-fat diet via the gut microbiota-adipose tissue axis. [Abstract]2025 May 16:10:101084. PMID: 40491530 -
Cell Rep
Temporal dynamics of immune cell transcriptomics in brain metastasis progression influenced by gut microbiome dysbiosis. [Abstract]2025 Feb 28;44(3):115356. PMID: 40023843 -
Emerg Microbes Infect
AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]2024 Dec;13(1):2321981. PMID: 38422452 -
Emerg Microbes Infect
2022 Dec;11(1):815-828. PMID: 35191819 -
Virulence
Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus. [Abstract]2024 Dec;15(1):2415952. PMID: 39390774 -
Virulence
Unraveling host-pathogen dynamics in a murine Model of septic peritonitis induced by vancomycin-resistant Enterococcus faecium. [Abstract]2024 Dec;15(1):2367659. PMID: 38951957 -
J Agric Food Chem
Lactiplantibacillus plantarum-Derived Indole-3-lactic Acid Ameliorates Intestinal Barrier Integrity through the AhR/Nrf2/NF-κB Axis. [Abstract]2024 Apr 10. PMID: 38597152 -
Microb Biotechnol
Attenuator LRR - a regulatory tool for modulating gene expression in Gram-positive bacteria. [Abstract]2021 Nov;14(6):2538-2551. PMID: 33720523 -
Biochem Pharmacol
MNAM enhances Blautia abundance and modulates Th17/Treg balance to alleviate diabetes in T2DM mice. [Abstract]2024 Dec;230(Pt 2):116593. PMID: 39454734 -
Life Sci
Drinking water temperatures modulate gut microbiota-L-cysteine axis to enhance adipose thermogenesis and alleviate obesity-related metabolic disorders in mice. [Abstract]2026 Jul 15:397:124438. PMID: 42097400 -
Life Sci
Electroacupuncture preserves intestinal barrier integrity through modulating the gut microbiota in DSS-induced chronic colitis. [Abstract]2020 Nov 15:261:118473. PMID: 32971101 -
Food Funct
Tryptophan metabolites derived from Lactiplantibacillus plantarum Y42 regulate the AhR/Nrf2/NF-κB axis to ameliorate colitis in mice. [Abstract]2026 Apr 14;17(7):3324-3335. PMID: 41860418 -
-
Food Funct
Bifidobacterium breve M-16V alleviates cow's milk allergy by regulating the gut microbiota and metabolites in human microbiota-associated mice. [Abstract]2025 Jul 14;16(14):5885-5899. PMID: 40600295 -
Transl Res
SIK2 protects against renal tubular injury and the progression of diabetic kidney disease. [Abstract]2023 Mar:253:16-30. PMID: 36075517 -
Biomacromolecules
Highly Efficient Thiol-Michael Addition Post-Modification toward Potent Degradable Antibacterial Polyesters with Guanidine Moiety. [Abstract]2025 Jun 9;26(6):3852-3867. PMID: 40335887 -
Front Microbiol
Repurposing Antispasmodic Agent Otilonium Bromide for Treatment of Staphylococcus aureus Infections. [Abstract]2020 Jul 31:11:1720. PMID: 32849366 -
Int Immunopharmacol
Early-life antibiotic dysbiosis impairs microbial tryptophan- nicotinic acid metabolism exacerbating food allergy in adulthood. [Abstract]2025 Jun 26:159:114888. PMID: 40403504 -
BMC Microbiol
Drug repurposing: antimicrobial and antibiofilm effects of MLS0315771 against Gram-positive bacteria. [Abstract]2026 Apr 29. PMID: 42056861 -
Front Pharmacol
Correction: Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo. [Abstract]2025 Dec 1:16:1657343. PMID: 41403439 -
ACS Omega
In Vitro Inhibition of Growth, Biofilm Formation, and Persisters of Staphylococcus aureus by Pinaverium Bromide. [Abstract]2023 Mar 6;8(10):9652-9661. PMID: 36936302 -
ACS Omega
Antibacterial and Antibiofilm Activities of Sertindole and Its Antibacterial Mechanism against Staphylococcus aureus. [Abstract]2023 Feb 3;8(6):5415-5425. PMID: 36816695 -
Front Aging Neurosci
Transplantation of fecal microbiota from APP/PS1 mice and Alzheimer's disease patients enhanced endoplasmic reticulum stress in the cerebral cortex of wild-type mice. [Abstract]2022 Jul 28;14:858130. PMID: 35966768 -
ACS Omega
Lapatinib Acts against Biofilm Formation and the Hemolytic Activity of Staphylococcus aureus. [Abstract]2022 Mar 3;7(10):9004-9014. PMID: 35309438 -
PLoS Pathog
2025 Jun 9;21(6):e1013179. PMID: 40489568 -
Mol Pharm
2022 Nov 7;19(11):4320-4332. PMID: 36269563 -
Appl Microbiol Biotechnol
2022 Apr;106(7):2689-2702. PMID: 35338386 -
ACS Infect Dis
Repurposing GSK2018682 Confers Dual Antibacterial and Antibiofilm Activity against Staphylococcus aureus. [Abstract]2026 Feb 13;12(2):623-636. PMID: 41525229 -
ACS Infect Dis
Derazantinib Inhibits the Planktonic Growth and Biofilm Formation of Staphylococcus aureus by Binding Membrane Phospholipids and Disrupting the Cell Membrane. [Abstract]2025 Jun 13;11(6):1473-1485. PMID: 40367508 -
iScience
AF6 regulates intestinal IgA via crosstalk between intestinal epithelial cells and immune cells in inflammatory bowel disease. [Abstract]2025 May 13;28(7):112658. PMID: 40687779 -
iScience
Gut microbiota from voluntary exercised mice protects the intestinal barrier by inhibiting neutrophil extracellular trap formation. [Abstract]2025 May 27;28(6):112763. PMID: 40585508 -
ACS Infect Dis
Loratadine Derivative Lo-7: A Weapon against Drug-Resistant Enterococcus and Streptococcal Infections. [Abstract]2024 Aug 9;10(8):2961-2977. PMID: 39066703 -
ACS Infect Dis
Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. [Abstract]2024 Apr 12;10(4):1327-1338. PMID: 38567846 -
ACS Infect Dis
Thiazolopyrimidinone Derivative H5-23 Enhances Daptomycin Activity against Linezolid-Resistant Enterococcus faecalis by Disrupting the Cell Membrane. [Abstract]2023 Dec 8;9(12):2523-2537. PMID: 38014911 -
iScience
Analysis of microbiota reveals the underlying mechanism of PHF11 in the development of Enterococcus-regulated endometriotic cysts. [Abstract]2023 Oct 7;26(11):108158. PMID: 37915596 -
iScience
Cinacalcet exhibits rapid bactericidal and efficient anti-biofilm activities against multidrug-resistant Gram-positive pathogens. [Abstract]2023 Mar 11;26(4):106378. PMID: 37034999 -
iScience
2022 Jan 5;25(2):103731. PMID: 35098100 -
ACS Infect Dis
Gallium Porphyrin and Gallium Nitrate Reduce the High Vancomycin Tolerance of MRSA Biofilms by Promoting Extracellular DNA-Dependent Biofilm Dispersion. [Abstract]2021 Aug 13;7(8):2565-2582. PMID: 34346692 -
-
Microbiol Spectr
In vitro persistence of clinical methicillin-resistant Staphylococcus aureus isolates from bone and joint infections after exposure to daptomycin, telavancin, and vancomycin. [Abstract]2025 Oct 23:e0157625. PMID: 41128537 -
Microbiol Spectr
Montelukast treats Streptococcus pneumoniae-induced sepsis via antibacterial and anti-inflammatory activities. [Abstract]2025 Oct 15:e0122125. PMID: 41090944 -
Microbiol Spectr
Clemastine Inhibits the Biofilm and Hemolytic of Staphylococcus aureus through the GdpP Protein. [Abstract]2022 Apr 27;10(2):e0054121. PMID: 35234502 -
Naunyn Schmiedebergs Arch Pharmacol
5-aminosalicylic acid alleviates colitis and protects intestinal barrier function by modulating gut microbiota in mice. [Abstract]2025 Apr;398(4):3681-3695. PMID: 39352537 -
J Cell Physiol
Lactobacillus plantarum alleviates irradiation-induced intestinal injury by activation of FXR-FGF15 signaling in intestinal epithelia. [Abstract]2022 Mar;237(3):1845-1856. PMID: 34881818 -
AMB Express
Odoribacter laneus protects intestinal barrier by bile acid-FXR axis in acute pancreatitis. [Abstract]2026 May 20. PMID: 42162499 -
Pathology
In vitro activity of recently introduced Gram-positive-specific antimicrobial agents against Australian methicillin-resistant Staphylococcus aureus isolates. [Abstract]2026 Feb 6:S0031-3025(26)00393-4. PMID: 41760492 -
AMB Express
Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]2024 Dec 24;14(1):141. PMID: 39718732 -
Mol Immunol
Alteration of intestinal microecology by oral antibiotics promotes oral squamous cell carcinoma development. [Abstract]2022 Sep:149:94-106. PMID: 35803000 -
Int J Med Sci
N-acetylcysteine Ameliorates Vancomycin-induced Nephrotoxicity by Inhibiting Oxidative Stress and Apoptosis in the in vivo and in vitro Models. [Abstract]2022 Apr 11;19(4):740-752. PMID: 35582415 -
Microbiologyopen
2025 Oct;14(5):e70062. PMID: 40926309 -
Infect Drug Resist
In Vitro Activity of Vancomycin, Teicoplanin, Linezolid and Daptomycin Against Methicillin-Resistant Staphylococcus aureus Isolates Collected from Chinese Hospitals in 2018-2020. [Abstract]2021 Dec 16;14:5449-5456. PMID: 34949928 -
PLoS One
LubriShieldTM-A permanent urinary catheter coating that prevents uropathogen biofilm formation in vitro independent of host protein conditioning. [Abstract]2025 Jul 10;20(7):e0328167. PMID: 40638652 -
J Appl Microbiol
Insights into the antimicrobial effects of tafenoquine against enterococcus and its biofilms. [Abstract]2024 Jan 2;135(1):lxae001. PMID: 38178639 -
Curr Microbiol
Repurposing CD5789 as an Antimicrobial Agent Against MRSA and Its High Resistant Phonotypes. [Abstract]2023 May 31;80(7):230. PMID: 37256372 -
J Med Microbiol
In vitro activities of telithromycin against Staphylococcus aureus biofilms compared with azithromycin, clindamycin, vancomycin and daptomycin. [Abstract]2020 Jan;69(1):120-131. PMID: 31916929 -
Future Microbiol
2025 Oct 13:1-10. PMID: 41082411 -
Biochem Biophys Res Commun
Multi-omics approaches to explore the therapeutic mechanism for ginsenoside Rg1 against MASLD. [Abstract]2025 Aug 30:776:152161. PMID: 40527176 -
Basic Clin Androl
2025 Mar 7;35(1):9. PMID: 40055615 -
Pol J Microbiol
Mechanisms of Rapid Bactericidal and Anti-Biofilm Alpha-Mangostin In Vitro Activity against Staphylococcus aureus. [Abstract]2023 Jun 14;72(2):199-208. PMID: 37314356 -
-
-
-
-
-
Heliyon
Proteins extracted from pearl oyster (Pinctada martensii) with efficient accelerated wound healing in vitro through promoting cell proliferation, migration, and collagen formation. [Abstract]2024 Jan 6;10(1):e24239. PMID: 38234916 -
-
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299
Lösungsmittel & Löslichkeit
DMSO : 50 mg/mL (34.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (1.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (1.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (293 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9. [Content Brief]
[2]. Watanakunakorn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18. [Content Brief]
[3]. Warren CA, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013 Feb;57(2):689-96. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.6900 mL | 3.4501 mL | 6.9001 mL | 17.2503 mL |
| 5 mM | 0.1380 mL | 0.6900 mL | 1.3800 mL | 3.4501 mL | |
| 10 mM | 0.0690 mL | 0.3450 mL | 0.6900 mL | 1.7250 mL | |
| 15 mM | 0.0460 mL | 0.2300 mL | 0.4600 mL | 1.1500 mL | |
| 20 mM | 0.0345 mL | 0.1725 mL | 0.3450 mL | 0.8625 mL | |
| 25 mM | 0.0276 mL | 0.1380 mL | 0.2760 mL | 0.6900 mL | |
| 30 mM | 0.0230 mL | 0.1150 mL | 0.2300 mL | 0.5750 mL |
Vancomycin Related Classifications
HY-B0671 Related Classifications
Powered by Bioz